A new review in Blood Cancer Discovery outlines a key regulatory decision by an FDA committee that greenlights a new biomarker endpoint for accelerated drug approval in multiple myeloma and could cut a decade off the drug development process.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
